MedTrace Logo

Multi-center Clinical Study on Hemoperfusion of KHA80

NCT06233838 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2025-01-14

No results posted yet for this study

Summary

To evaluate the decreasing rate of blood IL-6, β2-MG and PTH in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.

Conditions

  • Uremia
  • Uremic Osteodystrophy
  • Dialysis Related Complication

Interventions

DEVICE

KHA80 hemoperfusion treatment

On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.

Sponsors & Collaborators

  • First Affiliated Hospital of Fujian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2026-02-28
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06233838 on ClinicalTrials.gov